3 not yet recruiting, 2 active not recruiting, 2 recruiting, 1 completed. 3 Phase 3, 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Not yet recruiting 2, Active not recruiting 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow FLOT Chemotherapy: new trials by email Literature Review of FLOT Chemotherapy trials Research Report on FLOT Chemotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC. FLOT Chemotherapy, Durvalumab - Gastric, Esophagogastric Junction | Phase 3 | Not yet recruiting | AstraZeneca | 140 | 2026-11-30 | 2026-10-16 |
| Pathological Response to Perioperative FLOT in Gastric Adenocarcinoma FLOT Chemotherapy - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Not yet recruiting | Fundación Santa Fe de Bogota | 90 | 2026-10-01 | 2026-10-05 | |
| A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma Tislelizumab, FLOT Chemotherapy - Esophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma | Phase 1 | Recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 18 | 2025-12-12 | 2025-12-19 |
| A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma Sonesitatug Vedotin, Rilvegostomig, Trastuzumab Deruxtecan (T-DXd) - Gastroesophageal Adenocarcinoma | Phase 2 | Recruiting | AstraZeneca | 100 | 2025-07-17 | 2026-10-16 |
| Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer Chemotherapy - Gastric Cancer, Neoadjuvant Chemotherapy | Phase 3 | Not yet recruiting | Ruijin Hospital | 246 | 2021-09-01 | 2021-07-19 |
| Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer Durvalumab, FLOT chemotherapy - Gastrointestinal Neoplasms, Esophagogastric Junction | Phase 3 | Active not recruiting | AstraZeneca | 957 | 2020-11-17 | 2025-12-24 |
| Radiomics and Molecular Expression Predictive Model for Esophago-Gastric Junction and Gastric Cancer TRG CT scan - Gastric Cancer, Adenocarcinoma of the Stomach | Active not recruiting | University of Roma La Sapienza | 138 | 2019-12-20 | 2024-05-09 | |
| Dragon III: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer FLOT Chemotherapy, SOX Chemotherapy - Gastric Cancer, Chemotherapy Effect | Phase 2 | Completed | Ruijin Hospital | 74 | 2018-08-24 | 2025-07-23 |
Stomach Neoplasms (6) · Adenocarcinoma (1) · Adenocarcinoma Of Esophagus (1) · Gastrointestinal Neoplasms (1)
AstraZeneca (3) · Ruijin Hospital (2) · Fundación Santa Fe de Bogota (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · University of Roma La Sapienza (1)
China (3) · Canada (2) · Germany (2) · Italy (2) · Japan (2) · Netherlands (2) · Poland (2) · Spain (2) · Taiwan (2) · Turkey (Türkiye) (2) · United Kingdom (2) · United States (2) · Argentina (1) · Belgium (1) · Brazil (1)
Chen Li, PH D (2) · Zhenggang Zhu, PH D (2) · Birendra K Sah, PH D (1) · Birendra Kumar Sah, PH D (1) · Florian Lordick, Prof. Dr. (1) · Salah Eddin Al-Batran, Prof. Dr. (1)
PMID 33257672, PMID 35179774, PMID 35535555, PMID 35623069, PMID 40454643, PMID 41181842, PMID 42716074
2019 (1)